Latest & greatest articles for atorvastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atorvastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atorvastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atorvastatin

41. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease

Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease 19231315 2009 02 23 2009 03 27 2015 11 19 1879-1913 103 5 2009 Mar 01 The American journal of cardiology Am. J. Cardiol. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering (...) [IDEAL] study). 577-82 10.1016/j.amjcard.2008.10.029 The efficacy and safety of atorvastatin (80 mg/day) versus simvastatin (20 to 40 mg/day) in older (age >or=65 years) versus younger (<65 years) patients were assessed in a prespecified secondary analysis of the 8,888 patients with myocardial infarction in the IDEAL trial, a randomized open-label study. Several cardiovascular end points were evaluated, including the occurrence of a first major coronary event (MCE; nonfatal myocardial infarction

EvidenceUpdates2009

42. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event

Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event 19195498 2009 02 06 2009 03 19 2016 12 15 1879-1913 103 4 2009 Feb 15 The American journal of cardiology Am. J. Cardiol. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event. 437-41 10.1016/j.amjcard.2008.10.008 In addition to inhibiting (...) to inhibit ROCK activity. Accordingly, we enrolled 30 men with stable atherosclerosis (low-density lipoprotein [LDL] > or =100 mg/dL) in a randomized, double-blind study comparing equivalent LDL-lowering doses of a hydrophilic statin (rosuvastatin 10 mg once a day) with a lipophilic statin (atorvastatin 40 mg once a day) for 28 days. We assessed the change in lipids, ROCK activity, and flow-mediated dilation (FMD) of the brachial artery before and after statin therapy. Both treatment groups exhibited

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

43. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia 19195513 2009 02 06 2009 03 19 2015 11 19 1879-1913 103 4 2009 Feb 15 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. 515-22 10.1016/j.amjcard.2008.10.025 In patients with mixed dyslipidemia characterized by increased triglycerides (TG), decreased (...) high-density lipoprotein (HDL) cholesterol, and increased low-density lipoprotein (LDL) cholesterol, monotherapy with lipid-altering drugs often fails to achieve all lipid targets. This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia. A total of 613 patients with LDL cholesterol > or =130 mg/dl, TG > or =150 mg/dl, and HDL cholesterol <40 mg/dl for men and <50 mg/dl for women were randomly assigned

EvidenceUpdates2009

44. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial

Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial (...) Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jonsson B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions

NHS Economic Evaluation Database.2009

45. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based (...) of intensive (80mg) versus moderate (10mg) atorvastatin treatment to reduce cardiovascular events in patients with stable coronary heart disease in the UK, Spain, and Germany. The authors concluded that 80mg atorvastatin appeared to be a cost-effective approach for the secondary prevention of cardiovascular events across all three countries. The study methods were transparent and the analysis was comprehensive. The authors’ conclusions should be considered a fair assessment of their findings. Type

NHS Economic Evaluation Database.2009

46. Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada

Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada Cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada Khoury H, Wagner M, Merikle E, Johnson SJ, Roberts C Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes. The authors concluded that their study supported the cost-effectiveness

NHS Economic Evaluation Database.2009

47. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared (...) with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlof B, Sever PS, Wedel H, Jonsson B, Anglo-Scandinavian Cardiac Outcomes Trial investigators Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

NHS Economic Evaluation Database.2009

48. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea

Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine (...) and atorvastatin for the primary prevention of cardiovascular disease in Korea Liew D, Park HJ, Ko SK Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of a single-tablet fixed-dose combination of amlodipine

NHS Economic Evaluation Database.2009

49. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma

Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma 18757458 2008 11 21 2009 02 23 2015 11 19 1468-3296 63 12 2008 Dec Thorax Thorax Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. 1070-5 10.1136/thx.2008.100198 Statins have anti-inflammatory properties that may be beneficial in the treatment of asthma. A study was undertaken to test the hypothesis that atorvastatin (...) added to inhaled corticosteroids improves lung function and airway inflammation in atopic adults with asthma. 54 adults with atopic asthma were recruited to a double-blind randomised controlled crossover trial comparing the effect of oral atorvastatin 40 mg daily with that of a matched placebo on asthma control and airway inflammation. Each treatment was administered for 8 weeks separated by a 6-week washout period. The primary outcome was morning peak expiratory flow (PEF). Secondary outcomes

EvidenceUpdates2009

50. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease

Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease 19026302 2008 11 25 2008 12 22 2015 11 19 1879-1913 102 11 2008 Dec 01 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary (...) heart disease. 1489-94 10.1016/j.amjcard.2008.09.075 The aim of this study was to evaluate the efficacy and safety of ezetimibe 10 mg added to atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in patients with hypercholesterolemia at moderately high risk for coronary heart disease who did not reach low-density lipoprotein (LDL) cholesterol levels <100 mg/dl with atorvastatin 20 mg. In this 6-week, multicenter, double-blind, randomized, parallel-group study, 196 patients treated with atorvastatin 20

EvidenceUpdates2009

51. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease

Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease 19026303 2008 11 25 2008 12 22 2015 11 19 1879-1913 102 11 2008 Dec 01 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary (...) heart disease. 1495-501 10.1016/j.amjcard.2008.09.076 The percentage of change from baseline in low-density lipoprotein (LDL) cholesterol after the addition of ezetimibe 10 mg to atorvastatin 40 mg was compared with uptitration to atorvastatin 80 mg. In this multicenter, double-blind, parallel-group study, adult hypercholesterolemic patients using atorvastatin 40 mg/day were randomly assigned to atorvastatin 40 mg plus ezetimibe 10 mg or uptitration to atorvastatin 80 mg. After 6 weeks of treatment, compared

EvidenceUpdates2009

52. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials

Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials 19064019 2008 12 09 2008 12 18 2015 11 19 1879-1913 102 12 2008 Dec 15 The American journal of cardiology Am. J. Cardiol. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. 1654-62 10.1016/j.amjcard.2008.08.014 The benefit from statin therapy is proportional (...) to the low-density lipoprotein (LDL) cholesterol reduction. However, adverse events appear to be related to dose rather than LDL cholesterol reduction. Although serious side effects are rare, any comparison of statins requires scrutiny of the relation between therapeutic effect and risk of side effects. This report sought to determine whether the additional LDL cholesterol lowering with rosuvastatin over atorvastatin could be obtained without increased risk of short-term adverse events. Twenty-five studies (approximately

EvidenceUpdates2009

53. Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease

Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease Article Text Therapeutics Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable

Evidence-Based Medicine (Requires free registration)2008

54. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of rosuvastatin in comparison with atorvastatin, simvastatin, and pravastatin for managing lipid parameters in patients with hypercholesterolaemia. The authors

NHS Economic Evaluation Database.2008

55. Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy

Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy Alonso R, Fernandez de Bobadilla J, Mendez I, Lazaro P, Mata N, Mata P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of various preventive lifetime lipid-lowering interventions for patients with a genetic diagnosis of familial hypercholesterolaemia. The authors concluded that atorvastatin 80mg monotherapy was cost-effective and the addition of ezetimibe led

NHS Economic Evaluation Database.2008

56. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes

An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes Ramsey S D, Clarke L D, Roberts C S, Sullivan S D, Johnson S J, Liu L Z Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study determined the cost-effectiveness of atorvastatin, compared with no statin therapy, for the primary prevention of cardiovascular (CV) events in patients with Type 2 diabetes, normal low-density lipoprotein cholesterol, no history of CV disease, but one additional risk factor for CV

NHS Economic Evaluation Database.2008

57. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin

A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin Rogers S L, Magliano D J, Levison D B, Webb K, Clarke P J, Grobler M P, Liew D CRD summary The authors concluded that atorvastatin appears more effective than (...) simvastatin in reducing total cholesterol, low-density lipoprotein cholesterol and triglycerides, with a dose equivalence of between 1:2 and 1:4. Simvastatin appears more effective than atorvastatin in increasing high-density lipoprotein cholesterol, with no indication of dose-equivalence. The review was generally well-conducted and these conclusions seem likely to be reliable. Authors' objectives To assess the relative potency of atorvastatin and simvastatin in altering serum lipid levels. Searching

DARE.2007

58. Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario

Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Cost-effectiveness and budget impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events lowering within the SUS scenario Araujo D V, Bahia L (...) , Souza C P, Pavao A L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of rosuvastatin versus atorvastatin for lowering low-density lipoprotein-cholesterol and avoiding future cardiovascular

NHS Economic Evaluation Database.2007

59. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS) Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin (...) atorvastatin treatment, at doses of 10 mg daily, with placebo for the primary prevention of cardiovascular disease (CVD) in patients with Type 2 diabetes. Data from the Collaborative Atorvastatin Diabetes Study (CARDS) were used (Colhoun et al. 2004, see 'Other Publications of Related Interest' below for bibliographic details). Besides evaluating global differences, the study also evaluated the effects in three patient risk groups within the trial. Type of intervention Primary prevention. Economic study

NHS Economic Evaluation Database.2007

60. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting

Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting Usher-Smith J (...) A, Ramsbottom T, Pearmain H, Kirby M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined switching the patients' medication from 10 or 20g atorvastatin to 20 or 40 mg simvastatin for the treatment of high cholesterol, and

NHS Economic Evaluation Database.2007